This was consistent with a recently published paper showing that complete ERK inhibition with a MEK inhibitor maximizes the responses of BRAFV600E thyroid cancers to radioiodine by inducing sustained re-differentiation [39]. The gene discussed is MAP2K7; the disease is thyroid cancer.